
INFEX Therapeutics
Developing and licensing drugs for critical pandemic infections.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
* | £2.3m | Early VC | |
Total Funding | 000k |
Related Content
Infex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of therapies for critical infectious diseases. Founded in 2016 as the AMR Centre by Dr. Peter Jackson, the company rebranded in 2020 to reflect a broader focus beyond antimicrobial resistance to include a wider range of high-priority viral and microbial diseases. The company is headquartered at Alderley Park in Cheshire, UK, a prominent life sciences hub.
The company's business model is centered on acquiring, developing, and out-licensing promising drug candidates. Infex identifies and in-licenses early-stage or pre-clinical assets, advances them through to clinical proof-of-concept, and then seeks to partner with larger pharmaceutical companies for late-stage development and commercialization. This strategy is supported by a mix of equity investment, partner revenues, and non-dilutive grants. The company has secured funding from investors including LifeArc, Bruntwood, and Catapult Ventures.
Dr. Peter Jackson, the founder and CEO, is a serial entrepreneur in the life sciences sector with experience in creating multiple companies focused on therapeutics. The leadership team includes Chief Scientific Officer Dr. Victoria Savage, an experienced microbiologist, and Chief Clinical Officer Professor Colm Leonard, a national advisor on antimicrobial resistance. The team's expertise guides the development of the company's pipeline, which includes multiple programs targeting severe infections. Key pipeline products include RESP-X for chronic lung infections caused by Pseudomonas aeruginosa, and MET-X, a metallo-beta-lactamase inhibitor designed to treat infections caused by drug-resistant bacteria, such as complicated urinary tract infections.
Keywords: anti-infective therapies, antimicrobial resistance, drug development, clinical-stage R&D, pharmaceutical licensing, pandemic preparedness, infectious diseases, biopharmaceutical, drug discovery, critical priority pathogens, metallo-beta-lactamase inhibitors, Pseudomonas aeruginosa, urinary tract infections, respiratory infections, AMR, antibiotic development, virology, microbiology, clinical trials, life sciences